PROCEPT BioRobotics (PRCT) Common Equity (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Common Equity for 7 consecutive years, with $340.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 11.85% year-over-year to $340.1 million in Q2 2026; TTM through Jun 2026 was $340.1 million, a 11.85% decrease from a year earlier, with the FY2025 full-year figure at $365.9 million, down 9.04% from the prior year.
• Common Equity was $340.1 million for Q2 2026 at PROCEPT BioRobotics, down from $347.7 million in the prior quarter.
• Over five years, Common Equity peaked at $402.2 million in Q4 2024 and troughed at $155.9 million in Q2 2023.
• A 5-year average of $288.2 million and a median of $272.4 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 230.38% in 2022 and slumped 34.82% in 2023, its largest moves.
• Over 5 years, Common Equity stood at $197.1 million in 2022, then jumped by 42.46% to $280.8 million in 2023, then surged by 43.27% to $402.2 million in 2024, then dropped by 9.04% to $365.9 million in 2025, then dropped by 7.05% to $340.1 million in 2026.
• The last three Common Equity figures came in at $340.1 million (Q2 2026), $347.7 million (Q1 2026), and $365.9 million (Q4 2025), per Business Quant data.